17 September 2020 : Clinical Research
Comparison of Clinical Outcomes in Patients with ST Elevation Myocardial Infarction with Percutaneous Coronary Intervention and the Use of a Telemedicine App Before and After the COVID-19 Pandemic at a Center in Beijing, China, from August 2019 to March 2020
Jing Nan1ABCDEG*, Shuai Meng1BCE, Hongyu Hu1CDE, Ruofei Jia1DEF, Wei Chen1DEF, Qun Li1DE, Tong Zhang1DEF, Ke Song1DEF, Yang Wang2ACDE, Zening Jin1ABCDEFDOI: 10.12659/MSM.927061
Med Sci Monit 2020; 26:e927061
Table 2 Baseline angiographic and primary percutaneous coronary intervention (primary PCI) of the app user group and non-app user group before and after the COVID-19 pandemic.
Patients before the pandemic (n=183) | *p value | Patients after the pandemic (n=60) | **p value | ***p value | |||
---|---|---|---|---|---|---|---|
App user group (n=25) | Non App user group (n=158) | App user group (n=8) | Non App user group (n=52) | ||||
Location of infarct-related artery | |||||||
Left main coronary artery | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.9%) | |||
Left anterior descending artery | 12 (48%) | 88 (55.7%) | 4 (50%) | 35 (67.3%) | |||
Left circumflex artery | 3 (12%) | 31 (19.6%) | 0 (0%) | 5 (9.6%) | |||
Right coronary artery | 10 (40%) | 39 (24.7%) | 4 (50%) | 11 (21.2%) | |||
Saphenous vein graft | 0 (0%) | 0 (0%) | 0.262 | 0 (%) | 0 (%) | 0.179 | 0.169 |
Location of infraction | |||||||
Anterior | 12 (48%) | 88 (55.7%) | 4 (50%) | 37 (71.2%) | |||
inferial | 12 (48%) | 59 (37.3%) | 4 (50%) | 14 (26.9%) | |||
lateral | 1 (4%) | 11 (7%) | 0.595 | 0 (0%) | 1 (1.9%) | 0.259 | 0.045 |
Preprocedural TIMI grade | |||||||
0 | 18 (72%) | 135 (85.4%) | 7 (87.5%) | 49 (94.2%) | |||
1 | 4 (16%) | 19 (12%) | 1 (12.5%) | 3 (5.8%) | |||
2 | 1 (4%) | 3 (1.9%) | 0 (0%) | 0 (0%) | |||
3 | 2 (8%) | 1 (0.6%) | 0.068 | 0 (0%) | 0 (0%) | 0.481 | 0.054 |
Postprocedural TIMI grade | |||||||
0 | 1 (4%) | 0 (0%) | 1 (12.5%) | 0 (0%) | |||
1 | 1 (4%) | 1 (0.6%) | 1 (12.5%) | 1 (1.9%) | |||
2 | 1 (4%) | 8 (5.1%) | 2 (25%) | 10 (19.2%) | |||
3 | 22 (88%) | 149 (94.3%) | 0.209 | 4 (50%) | 41 (78.8%) | 0.180 | 0.000 |
Lesion vessel number | |||||||
1 | 2 (8%) | 13 (8.2%) | 0 (0%) | 2 (3.8%) | |||
2 | 16 (64%) | 112 (70.9%) | 6 (75%) | 37 (71.2%) | |||
3 | 7 (28%) | 33 (20.9%) | 0.584 | 2 (25%) | 13 (25%) | 0.868 | 0.417 |
Risk stratification | |||||||
TIMI risk score | 5 (5–6) | 5 (5–6) | 0.076 | 5 (3.25–6.5) | 6 (5–7) | 0.403 | 0.781 |
GRACE risk score | 162.6± 87 | 164.44±201.7 | 0.367 | 174.00 ± 20.87 | 171.98±20.50 | 0.797 | 0.034 |
Syntax score | 26 (19.5–33) | 29 (24–33) | 0.407 | 23 (18–32.75) | 28.5 (22.25–33) | 0.210 | 0.824 |
Type of intervention | |||||||
PCI | 25 (100%) | 158 (100%) | 1.000 | 8 (100%) | 52 (100%) | 1.000 | 1.000 |
Type of stent | |||||||
Bare metal stent | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |||
drug-eluting stent | 25 (100%) | 158 (100%) | 1.000 | 8 (100%) | 52 (100%) | 1.000 | 1.000 |
Intra-operation procedure | |||||||
Thrombus aspiration | 6 (24.0%) | 35 (22.2%) | 0.800 | 3 (37.5%) | 12 (23.1%) | 0.400 | 0.725 |
Intra-aortic balloon counter-pulsation | 5 (20%) | 25 (15.8%) | 0.569 | 3 (37.5%) | 18 (34.6%) | 1.000 | 0.003 |
Temporary pacemaker | 2 (8%) | 5 (3.2%) | 0.245 | 1 (12.5%) | 2 (3.8%) | 0.354 | 0.712 |
Vasopressors | 10 (40%) | 64 (40.5%) | 1.000 | 4 (50%) | 31 (59.6%) | 0.708 | 0.017 |
Cardiogenic shock | 3 (12.0%) | 8 (5.1%) | 0.176 | 2 (25%) | 9 (17.3%) | 0.631 | 0.008 |
GPI | 24 (96%) | 153 (96.8%) | 0.591 | 8 (100%) | 50 (96.2%) | 1.000 | 1.000 |
predialation | 23 (92%) | 135 (85.4%) | 0.537 | 6 (75%) | 46 (88.5%) | 0.288 | 1.000 |
Total number of stents implanted | 1 (1–2) | 1 (1–2) | 0.237 | 1 (1–1.75) | 1 (1–2) | 0.384 | 0.343 |
Total stent length (mm) | 24 (18–47.5) | 29 (20–41.75) | 0.349 | 24 (21–32) | 26.5 (23–33) | 0.638 | 0.869 |
Post dialation | 23 (92.0%) | 118 (75.6%) | 0.074 | 8 (100%) | 41 (83.7%) | 0.330 | 0.589 |
Non-culprit lesion intervention | 0 (0%) | 0 (0%) | 1.000 | 0 (0%) | 0 (0%) | 1.000 | 1.000 |
Frequencies are reported as n/total (%), unless otherwise specified. TIMI – thrombolysis in myocardial infarction; GRACE – global registry of acute coronary events; GPI – glycoprotein IIb/IIIa inhibitor. * Comparison between App user and non-App user group after the pandemic; ** comparison between App user and non-App user group after the pandemic; *** comparison between patients before and after the pandemic. |